How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

10,985 results for

General Medical Books

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Books: ABC of Domestic and Sexual Violence: No Quick Fix — Aim to Recognise, Respond, and Refer (PubMed)

Books: ABC of Domestic and Sexual Violence: No Quick Fix — Aim to Recognise, Respond, and Refer 27231300 2017 05 19 2017 08 17 1478-5242 66 647 2016 Jun The British journal of general practice : the journal of the Royal College of General Practitioners Br J Gen Pract Books: ABC of Domestic and Sexual Violence: No Quick Fix - Aim to Recognise, Respond, and Refer. 320 10.3399/bjgp16X685573 Anderson Clementine C BSc Women's Health (King's College London), Fifth-Year Medical Student (University (...) of Southampton). E-mail: clementine.anderson@kcl.ac.uk. eng Journal Article England Br J Gen Pract 9005323 0960-1643 IM Books Domestic Violence Humans Medicine in Literature Sex Offenses 2016 5 28 6 0 2016 5 28 6 0 2017 5 20 6 0 ppublish 27231300 66/647/320-a 10.3399/bjgp16X685573 PMC4871297

Full Text available with Trip Pro

2016 The British Journal of General Practice

142. Seclusion in general psychiatry

of the healthcare professionals who monitored the patient. ? The logbook, which may be in digital form, must be presented on request to the departmental committee for psychiatric care (CDSP), to the Controller-General of Prisons or their delegates, and to Members of Parliament. DATA COLLECTION AND THE POLICY OF THE ESTABLISHMENT (CONTINUED) ? From the data collection, the care units, departments, sectors and the HCO medical committee (CME, commission médicale d’établissement) review the evolution in the number (...) of seclusion measures. The committee for hospital care, rehabilitation and medical technology (CSIRMT, commission des soins infirmiers, rééducation et médicotechnique) is involved in this work. The licensed psychiatric facility designated by the director general of the regional health authority to provide psychiatric care without consent should use this review as a basis to define a policy aimed at reducing the use of seclusion. This policy should be supported by the presence of multidisciplinary care

2017 HAS Guidelines

143. Reducing Readmission in Sickle Cell Disease: The Role of the Patient-Centered Medical Home

Reducing Readmission in Sickle Cell Disease: The Role of the Patient-Centered Medical Home Reducing Readmission in Sickle Cell Disease: The Role of the Patient-Centered Medical Home – Clinical Correlations Search Reducing Readmission in Sickle Cell Disease: The Role of the Patient-Centered Medical Home October 6, 2017 8 min read By Leonard Naymagon, MD Peer Reviewed Vaso-occlusive crisis (VOC), or pain crisis, is the most common clinical manifestation of sickle cell disease (SCD (...) ], [3]. Recent initiatives at many medical centers have demonstrated that the most effective improvements to the current model likely lie in easing and expanding access to specialized s [4], [5], [6], [7]. Such shifts in philosophy may significantly improve quality of life among SCD patients while significantly reducing costs associated with frequent hospital-based encounters. Patients with SCD should have regular follow-up with a specialized clinician and [6]. Given the relatively extensive

2017 Clinical Correlations

144. FAQ About Medical Student Electives

FAQ About Medical Student Electives FAQ About Medical Student Electives - CanadiEM FAQ About Medical Student Electives In by Brent Thoma March 1, 2017 This is a topic for which the “how to” seems to be passed down from senior to junior medical students and never written down. I remember being pretty clueless about this process when I went through it. I was a relative late-comer to the Royal College EM sweepstakes, having decided to pursue that program only during the summer before fourth year (...) this, hopefully you will not make the same mistakes! In this post, I’ll go through some FAQ’s about medical student electives. If you’re interested in this topic, I imagine my posts on , the , , and the overall will be of interest. As always, I’ll be focusing on the EM perspective (it’s what I know!), but this information is likely applicable to electives in multiple other specialties. Where should I do electives? Think of electives as your opportunity to take a program for a swing around the dance floor. Who

2017 CandiEM

145. Safe Medication Use in the ICU

. The medication use process can be divided into four categories: prescription, dispensing, administration, and monitoring. As such, the committee collectively developed clinical questions pertaining to MEs and ADEs addressing the steps of the medication use process. To ensure that the committee used a consistent approach, a general consensus was reached on the definitions of these terms ( ). Another important concept of safe medication use is the ME and ADE surveillance to capture events, either (...) of evidence statements, and one commentary on disclosure of drug-related events was developed. The committee determined appropriate keywords and medical subject heading (MeSH) terms that included at minimum: ME and/or ADEs crossed against the general topic area and the specific question for each section of the guidelines. A professional librarian (C.K.) reviewed and developed appropriate search strategies for each section. Search results were stored in an electronic, Web-based, password-protected database

Full Text available with Trip Pro

2017 Society of Critical Care Medicine

146. Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment)

awarded on: 13 August 2015 Internal Commission No.: A15-31 Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm) 50670 Cologne Germany Tel.: +49 (0)221 – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A15-31 Version 1.0 Tiotropium/olodaterol – Benefit assessment acc. to §35a Social Code Book V 12 Nov 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical (...) Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Tiotropium/Olodaterol – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 November 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A15-31

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

147. Pertuzumab (new therapeutic indication) - benefit assessment according to §35a Social Code Book V (dossier assessment)

Pertuzumab (new therapeutic indication) - benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Pertuzumab (neues Anwendungsgebiet) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 November 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A15-34 Pertuzumab (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-34 Version 1.0 Pertuzumab (new TI) – Benefit assessment acc. to §35a SGB V 27 November 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Pertuzumab (new therapeutic indication) – Benefit assessment according to §35a SGB V Commissioning agency

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

148. Evolocumab - benefit assessment according to §35a Social Code Book V

Evolocumab - benefit assessment according to §35a Social Code Book V Extract 1 Translation of Assessment module I, Sections I 2.1 to I 2.6, and Assessment module II, Sections II 2.1 to II 2.5, of the dossier assessment Evolocumab – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 December 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG (...) Reports – Commission No. A15-38 Evolocumab – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-38 Version 1.0 Evolocumab – Benefit assessment acc. to §35a Social Code Book V 11 December 2015 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Evolocumab – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 16 September 2015 Internal Commission No.: A15

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

149. Nivolumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment)

Nivolumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nivolumab (neues Anwendungsgebiet) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 November 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A15-32 Nivolumab (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-32 Version 1.0 Nivolumab (new TI) – Benefit assessment acc. to §35a Social Code Book V 12 Nov 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (new therapeutic indication) – Benefit assessment according to §35a SGB V Commissioning

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

150. Edoxaban: benefit assessment according to §35a Social Code Book V (dossier assessment)

Edoxaban: benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Assessment module I, Sections I 2.1 to I 2.6, and Assessment module II, Sections II 2.1 to II 2.5, of the dossier assessment Edoxaban – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 October 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A15-29 Edoxaban – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-29 Version 1.0 Edoxaban – Benefit assessment acc. to §35a Social Code Book V 28 October 2015 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Edoxaban – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 20 July 2015 Internal Commission

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

151. Pembrolizumab: benefit assessment according to §35a Social Code Book V (dossier assessment)

Commission No.: A15-33 Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm) 50670 Cologne Germany Tel.: +49 (0)221 – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A15-33 Version 1.0 Pembrolizumab – Benefit assessment acc. to §35a Social Code Book V 12 November 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Uwe Wollina, Hospital Dresden (...) 1.0 Pembrolizumab – Benefit assessment acc. to §35a Social Code Book V 12 November 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - 15 - Table 8: Planned duration of follow-up – RCT, direct comparison, pretreated patients: pembrolizumab vs. individual treatment Study Outcome Planned follow-up KEYNOTE 002 Overall survival Every 3 months until death Symptoms Up to 30 days after the last dose of the study medication or before the start of a new antineoplastic treatment Health

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

152. Nivolumab: benefit assessment according to §35a Social Code Book V (dossier assessment)

Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm) 50670 Cologne Germany Tel.: +49 (0)221 – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A15-27 Version 1.0 Nivolumab – Benefit assessment acc. to §35a Social Code Book V 13 October 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Uwe Wollina, Hospital Dresden-Friedrichstadt, Dresden (...) Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) IV intravenous IVRS interactive voice response system MedDRA Medical Dictionary for Regulatory Activities PD-L1 programmed cell death ligand 1 PT Preferred Term QLQ-C30 Quality of Life Questionnaire Core-30 RCT randomized controlled trial SAE serious adverse event SGB Sozialgesetzbuch (Social Code Book) SOC System Organ Class SPC Summary of Product Characteristics ULN upper limit of normal VAS visual analogue scale

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

153. Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment)

Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Insulin degludec/Liraglutid (neues Anwendungsgebiet) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11. November 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A15-30 Insulin degludec/liraglutide (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-30 Version 1.0 Insulin degludec/liraglutide (new TI) – Benefit assessment acc. to §35a SGB V 11 Nov 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin degludec/liraglutide (new

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

154. Netupitant/palonosetron: benefit assessment according to §35a Social Code Book V (dossier assessment)

Netupitant/palonosetron: benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Netupitant/Palonosetron – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 November 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A15-28 (...) Netupitant/palonosetron – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-28 Version 1.0 Netupitant/palonosetron– Benefit assessment acc. to §35a SGB V 12 November 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Netupitant/palonosetron – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

155. Lomitapide: benefit assessment according to §35a Social Code Book V (dossier assessment)

No.: A15-23 Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm) 50670 Cologne Germany Tel.: +49 (0)221 – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A15-23 Version 1.0 Lomitapide – Benefit assessment acc. to §35a Social Code Book V 10 September 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Manfred Gogol, Lindenbrunn Hospital (...) for concomitant treatment with LDL apheresis. The corresponding inclusion criterion merely specified that the present lipid-lowering medication Extract of dossier assessment A15-23 Version 1.0 Lomitapide – Benefit assessment acc. to §35a Social Code Book V 10 September 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - 15 - had to be stable for at least 6 weeks before the baseline examination. It could also not be inferred from any further information of the study that only patients

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

156. Secukinumab: benefit assessment according to §35a Social Code Book V (dossier assessment)

No.: A15-20 Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm) 50670 Cologne Germany Tel.: +49 (0)221 – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A15-20 Version 1.0 Secukinumab – Benefit assessment acc. to §35a Social Code Book V 28 August 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Michael Weichenthal, University Medical (...) Secukinumab: benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Secukinumab – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 August 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A15-20 Secukinumab – Benefit

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

157. Belatacept: benefit assessment according to § 35a Social Code Book V (dossier assessment)

No.: A15-25 Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm) 50670 Cologne Germany Tel.: +49 (0)221 – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A15-25 Version 1.0 Belatacept – Benefit assessment acc. to §35a Social Code Book V 13 October 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Reinhart T. Grundmann, District Hospitals (...) assessment acc. to §35a Social Code Book V 13 October 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - 9 - Table 5: Characteristics of the interventions – RCT, direct comparison: belatacept vs. ciclosporin A Study Belatacept Ciclosporin A Prior and concomitant medication BENEFIT Month 0–3: belatacept 10 mg/kg IV on days 1, 5 and in weeks 2, 4, 8 and 12 From month 4: belatacept 5 mg/kg IV every 4 weeks Daily starting dose: ciclosporin A oral 7 ± 3 mg/kg (4–10 mg/kg) Month 1: dose

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

158. Safinamide: benefit assessment according to §35a Social Code Book V (dossier assessment)

Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm) 50670 Cologne Germany Tel.: +49 (0)221 – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A15-18 Version 1.0 Safinamide – Benefit assessment acc. to §35a Social Code Book V 13 August 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Rüdiger Mielke, Chair of Neuroscience (...) , but the publications are from the years 1996 to 2003. Additional relevant entacapone study BIA-91067-301 Based on the available information, the BIA-91067-301 study is also generally comparable to the available studies in its patient characteristics and inclusion and exclusion criteria. As in Extract of dossier assessment A15-18 Version 1.0 Safinamide – Benefit assessment acc. to §35a Social Code Book V 13 August 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - 10 - the other studies, patients

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

159. Nintedanib - Benefit assessment according to §35a Social Code Book V (dossier assessment)

Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm) 50670 Cologne Germany Tel.: +49 (0)221 – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A15-01 Version 1.0 Nintedanib – Benefit assessment acc. to §35a Social Code Book V 30 March 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Marcus Wiedmann, Department of Internal Medicine I, St (...) . to §35a Social Code Book V 30 March 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - 11 - Nintedanib 200mg twice daily + docetaxel IV 75mg 2 every 3 weeks Nintedanib 200mg twice daily + docetaxel IV 75mg 2 every 3 weeks Randomization * Treatment discontinuation on disease progression, occurrence of certain predefined AEs or following the patient’s/ investigator’s decision; treatment with other anticancer medication possible on progression Placebo twice daily + docetaxel IV 75mg 2

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

160. Dulaglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)

No.: A15-07 Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm) 50670 Cologne Germany Tel.: +49 (0)221 – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A15-07 Version 1.0 Dulaglutide – Benefit assessment acc. to §35a Social Code Book V 29 April 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Andreas Barthel, Endokrinologikum Ruhr (...) Blood Sugar Survey LOCF last observation carried forward MedDRA Medical Dictionary for Regulatory Activities MMRM mixed-effects model repeated measures NVL Nationale VersorgungsLeitlinie (National Care Guideline) OAD oral antidiabetic PT Preferred Term RCT randomized controlled trial SAE serious adverse event SGB Sozialgesetzbuch (Social Code Book) SOC System Organ Class SPC Summary of Product Characteristics VAS visual analogue scale Extract of dossier assessment A15-07 Version 1.0 Dulaglutide

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>